Table 2.
Multivariable Analyses for Overall Survival and Non-relapse Mortality for Patients with CMV Viremia by Day 100 (N = 375)
| Overall survivala | Non-relapse mortalityb | |||||
|---|---|---|---|---|---|---|
| Characteristics | aHR | 95% CI | P value | aHR | 95% CI | P value |
| Age, y | ||||||
| 18–39 | ||||||
| 40–64 | 0.74 | (.37, 1.48) | .39 | .67 | (.26, 1.70) | .40 |
| 64+ | 1.93 | (.99, 3.75) | .05 | 2.24 | (.92, 5.45) | .07 |
| Underlying disease | ||||||
| Leukemia | ||||||
| Lymphoma | 0.76 | (.39, 1.47) | .41 | |||
| MDS | 0.87 | (.52, 1.46) | .60 | |||
| Other | 0.12 | (.02, .83) | .03 | |||
| Acute ≥ grade 2 GvHD | ||||||
| No | ||||||
| Yes | 1.96 | (1.28, 3) | .002 | 3.34 | (1.83, 6.08) | < .0001 |
| CMV D serostatus | ||||||
| D– | ||||||
| D+ | 1.67 | (1.07, 2.62) | .03 | 2.75 | (1.45, 5.22) | .002 |
| Study period | ||||||
| Before 2013 | ||||||
| After 2013 | 0.66 | (.42, 1.04) | .07 | 0.49 | (.27, .89) | .02 |
| CMV control status | ||||||
| Controllers | ||||||
| Non-controllers | 2.65 | (1.71, 4.12) | < .0001 | 5.02 | (2.82, 8.92) | < .0001 |
Abbreviations: CI, confidence interval; CMV, cytomegalovirus; GVHD, graft versus hostdisease; HR, hazard ratio; MDS, myelodysplastic syndrome.
aCox proportional hazards regression models were used for overall survival.
bFine and Gray proportional subdistribution hazards regression models were used for non-relapse mortality. Relapse was considered as competing risk event.